Cogstate Ltd · ASX:CGS
Cogstate — Shareholder Meeting (November 2022)
21 slides from Cogstate's shareholder meeting presentation, Nov 4, 2022
Slide 1: 2022 Annual General Meeting Presentation
ASX Announcement 4 November 2022 For personal use only 2022 Annual General Meeting Presentation Cogstate Limited (ASX.CGS) attaches its 2022 Annual General Meeting Presentation, being presented to shareholders at today’s meeting. This announcement was authorised for release by a sub-committee of the
Slide 2: Annual General Meeting
For personal use only Annual General Meeting Friday 4 November 2022 Start Time: 11am Australian Eastern Summer Time © 2022 Cogstate Ltd. All rights reserved.
Slide 3: Disclaimer
Disclaimer For personal use only This presentation has been prepared by Cogstate Limited (‘Cogstate’). The information in this presentation is of a general nature and does not purport to be complete, nor does it contain all the information which would be required in a prospectus prepared in accordan
Slide 4: Online Q&A
Online Q&A For personal use only 3. Hit enter on your 1. Click on the Q&A icon 2. Type your question in keyboard to submit your the new Q&A window message To contact support: Please call 1300 816 159 (within Australia) or +61 2 8072 1479 (outside of Australia) 3
Slide 5: Registration and Voting
Registration and Voting For personal use only 1. Log in or register at: 2. Click view and register 3. Record your vote. Once https://investor.automic.com.au/#/home your attendance for the you confirm it is lodged meeting and final To contact support: Call 1300 816 159 4
Slide 6: Board of Directors
Board of Directors For personal use only Martyn Myer Brad O’Connor Non-Executive Chairman Managing Director / CEO Member: Audit, Risk & Compliance Committee Chair: Remuneration & Nomination Committee David Dolby Richard Mohs Non-Executive Director Non-Executive Director Member: Remuneration & Nomina
Slide 7: Our mission to democratize brain health assessment
For personal use only We are on a mission to democratize brain health assessment across clinical research and clinical care... combining proven science with disruptive digital innovation to make the measurement of cognition as simple, standardized, actionable and common as the measurement of blood p
Slide 8: Leaders in the Measurement of Cognition
Leaders in the Measurement of Cognition For personal use only Clinical Trials Healthcare Academic Research Scientific consulting, Computerized testing solution Computerized cognitive testing computerized cognitive testing, for clinical care (FDA cleared adopted in 1,800+ studies including rater trai
Slide 9: Eisai Global License
Eisai: Focusing on dementia as global pioneer since Global License For personal use only Aricept launch in 1997 • 2 x 10-year licenses (Japan & Rest-Of-World) • Excludes Clinical Trials business • Total upfront payment of US$16m across 2 agreements already received • Additionally, Cogstate receives
Slide 10: Current Status: Potential Therapies
Current Status : Potential Therapies For personal use only External Catalysts: LECANEMAB GANTENERUMAB DONANEMAB Important phase 3 data Positive data released Topline data from phase 3 Started rolling submission from key Alzheimer's late September showing Graduate study for accelerated approval trial
Slide 11: Implications of Alzheimer's Treatment on Market
Implications of Alzheimer’s Treatment on Market For personal use only Clinical Trials Healthcare Larger market for Cogstate tech & services with With treatment options, patient demand for increased investment in new therapeutics. cognitive assessment will grow. • In other areas of medicine, an initi
Slide 12: FY22 Financial Highlights
FY22 Financial Highlights (All figures in US$) Strong earnings growth and solid cash position For personal use only Record clinical sales contracts executed Record contracted future revenue $82.5m $139.1m Alzheimer’s disease represented 84% of +74% the value of contracts executed in FY22 +37% Strong
Slide 13: External Factors Impacting Our Business
External Factors Impacting Our Business For personal use only Alzheimer’s R&D Alzheimer’s Increased R&D spend positively R&D impacting Cogstate Clinical Trials sales Virtual Assessment Virtual Decentralised trial design, with at-home Assessment virtual assessment, has complemented our offering Chann
Slide 14: Clinical Trials Sales Contracts
Clinical Trials Sales Contracts 1Q23 sales contracts performance only 90 • $17.9m executed in 1Q23 – our 3rd highest 80 Quarter on record 8.8 ➢ Down 56% compared to PCP - 1Q22 use 70 19.2 was a record result for Cogstate. 60 $40.8m included one large Phase 3 US$ Millions contract. For personal 50 13
Slide 15: Contracted Future Revenue
Contracted Future Revenue Year-On-Year Growth in Contracted Future Revenue only 150 140 The long-dated contractual nature of Cogstate revenue provides revenue 130 predictability and insight into future revenue 120 performance. use 110 100 $148.3m of Contracted Future Revenue as at 30-Sep-22, up 14%
Slide 16: Group Revenue
Group Revenue • 1Q23 revenue of $8.9m, down from recent quarters reflecting delays in some Clinical Trials studies For personal use only • Slower than expected patient enrolment in a small number Alzheimer’s studies has delayed recognition of revenue during 1Q23. • The timing issue in respect of rev
Slide 17: Contracted Future Revenue Run-Off
Contracted Future Revenue Run-Off 40 Contracted Future For personal use only Revenue is Growing 35 3.1 4.2 This time last year, FY23 contracted revenue was $30.9m (of which $26.7m related to Clinical Trials), 30 4.2 whereas today our FY24 contracted revenue is $36.0m (of which $31.8m relates to Clin
Slide 18: FY23 Business Update
FY23 Business Update For personal use only 1. Pharma companies are planning additional Alzheimer’s trials to support ongoing research • Subcutaneous injection trials to show evidence of continued efficacy with different delivery mechanism • Trial of drug cessation and maintenance regimen • Expansion
Slide 19: FY 2023 Guidance
Clinical Trials Revenue: • 1H23 now expected to be down 10% - 12% on most recent half year (2H22) For personal use only • Prior Year: 2H22 Clinical Trials revenue $19.5m • First Quarter: 1Q23 Clinical Trials revenue $7.8m • 2H23 will vary according to sales contracts executed and therefore, based on
Slide 20: Cogstate Positioned For Growth
Cogstate Positioned For Growth For personal use only New Therapies Financial Alzheimer’s disease Strength breakthroughs are Profitable and cashflow positive for Cogstate’s positive with $148.3m business revenue backlog Product Channel Revenue Offering Strategy Short-term revenue delays are expected
Slide 21: Cogstate
B Cogstate Ajuo esn feuosied 105